Atrility Medical

Atrility Medical addresses a critical gap in post-cardiac surgery care by commercializing the AtriAmp, an FDA-cleared medical device that delivers continuous atrial electrograms to the bedside monitor. This technology provides clinicians with the gold-standard signal for arrhythmia diagnosis in real-time, potentially reducing diagnostic delays, preventing inappropriate treatments, and improving patient outcomes. The company targets pediatric and adult cardiac ICUs, leveraging strong clinical testimonials and published data showing improved diagnostic accuracy and confidence. Atrility appears to be a commercial-stage, private company driving adoption of its novel monitoring solution.

A hardware interface device that connects temporary atrial pacing wires to standard ICU patient monitors and external pacemakers, providing continuous, real-time amplification and display of atrial electrogram (AEG) signals.

The AtriAmp appears first-in-class for providing continuous atrial electrograms on the bedside monitor. Traditional competition is the manual, intermittent method of obtaining AEGs via a 12-lead ECG adapter or makeshift connections, which the AtriAmp aims to obsolete. Potential future competitors include large cardiac monitoring companies (e.g., GE Healthcare, Philips, Medtronic) that could develop integrated solutions, though Atrility currently holds a novelty and focus advantage.